382 related articles for article (PubMed ID: 25550384)
1. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
Levy-Lahad E; Lahad A; King MC
J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
[No Abstract] [Full Text] [Related]
2. Unknown significance.
Couzin-Frankel J
Science; 2014 Dec; 346(6214):1167-70. PubMed ID: 25477439
[No Abstract] [Full Text] [Related]
3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
4. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
5. [Genetic testing in patients at risk for carcinoma of the breast].
Kiechle M
Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
[No Abstract] [Full Text] [Related]
6. Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence.
Levy-Lahad E
Genet Med; 2009 Sep; 11(9):620-1. PubMed ID: 19690506
[No Abstract] [Full Text] [Related]
7. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
8. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
9. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
[TBL] [Abstract][Full Text] [Related]
11. Variability in Cancer Risk with BRCA Mutations.
Cancer Discov; 2015 Jul; 5(7):OF16. PubMed ID: 25952264
[No Abstract] [Full Text] [Related]
12. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract][Full Text] [Related]
14. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
[No Abstract] [Full Text] [Related]
15. High frequency of the recurrent c.1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control.
Laarabi FZ; Ratbi I; Elalaoui SC; Mezzouar L; Doubaj Y; Bouguenouch L; Ouldim K; Benjaafar N; Sefiani A
BMC Res Notes; 2017 Jun; 10(1):188. PubMed ID: 28577564
[TBL] [Abstract][Full Text] [Related]
16. Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view.
De Felice F; Marchetti C
Oncotarget; 2015 Nov; 6(37):39391-2. PubMed ID: 26588056
[No Abstract] [Full Text] [Related]
17. Prevention and Screening in Hereditary Breast and Ovarian Cancer.
Zeichner SB; Stanislaw C; Meisel JL
Oncology (Williston Park); 2016 Oct; 30(10):896-904. PubMed ID: 27753056
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.
Kaldate R; Huston A; McCoy H; Cardeiro D; Noyes K
Breast J; 2014; 20(3):325-6. PubMed ID: 24708220
[No Abstract] [Full Text] [Related]
19. Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.
Lynce F; Isaacs C
J Natl Compr Canc Netw; 2016 Jun; 14(6):809-12. PubMed ID: 27283172
[No Abstract] [Full Text] [Related]
20. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]